Press release
Chronic Myeloid Leukemia Pipeline: Driving Innovation with 25+ Pioneering Companies Advancing Groundbreaking Therapies
Chronic Myeloid Leukemia Pipeline
DelveInsight's "Chronic Myelocytic Leukemia Pipeline Insight, 2025" comprehensively analyzes the current clinical landscape and growth prospects in the Chronic Myelocytic Leukemia market. The report covers disease insights, treatment guidelines, and a detailed pipeline assessment from preclinical to marketed stages. It includes drug mechanisms, clinical studies, regulatory progress, and key developments such as collaborations, mergers, funding, and designations.
For emerging Chronic Myelocytic Leukemia drugs, the Chronic Myelocytic Leukemia pipeline analysis report provides a 360° view of the therapeutics landscape by development point, product type, route of administration, molecule type, and MOA. The pipeline research covers business opportunities, challenges, future partnerships, strong competitors, and growth strategies.
Key Takeaways from the Chronic Myelocytic Leukemia Pipeline Report
• DelveInsight's Chronic Myelocytic Leukemia Pipeline analysis depicts a robust space with 25+ active players working to develop 25+ pipeline drugs for Chronic Myelocytic Leukemia treatment.
• The leading Chronic Myelocytic Leukemia companies include Novartis Oncology, Servier, Eltrombopag, Immune-Onc Therapeutics, H3 Biomedicine, Chroma Therapeutics, Nerviano Medical Sciences, Astex Pharmaceuticals, Takeda Oncology, Argenx, Kura Oncology, Incyte Corporation, Genentech, Inc., Sensei Biotherapeutics, Pfizer, BioLite, Inc., Newave Pharmaceutical Inc., Ellipses Pharma, Eli Lilly and Company, Aprea Therapeutics, Treadwell Therapeutics, Prelude Therapeutics, Onconova Therapeutics, Immune Pharmaceuticals, Teva Pharmaceutical Industries, and others are evaluating their lead assets to improve the Chronic Myelocytic Leukemia treatment landscape.
• Key Chronic Myelocytic Leukemia pipeline therapies in various stages of development include Imatinib, Radotinib, Olverembatinib, Venetoclax, Sabatolimab, Enasidenib, and others.
• In January 2025, Handa Pharmaceuticals announced that its U.S. subsidiary, Handa Therapeutics, acquired PHYRAGO (dasatinib) tablets, an FDA-approved treatment for chronic myeloid leukemia developed by Nanocopoeia. PHYRAGOTM is the first dasatinib product that can be co-administered with gastric acid-reducing agents.
• In November 2024, the FDA approved a reformulated version of nilotinib (Danziten) for adults with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia (CML) in the chronic phase, and for those with chronic or acute-phase disease resistant or intolerant to prior imatinib treatment.
• In October 2024, Novartis announced that the FDA granted accelerated approval for SCEMBLIX (asciminib) for adults with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in the chronic phase (Ph+ CML-CP).
Request a sample and discover the recent breakthroughs happening in the Chronic Myelocytic Leukemia pipeline landscape @ https://www.delveinsight.com/report-store/chronic-myelocytic-leukemia-cml-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr
Chronic Myelocytic Leukemia Overview
Chronic Myelomonocytic Leukemia (CMML) is a rare type of leukemia characterized by an elevated number of monocytes in the blood and bone marrow. Although it includes "leukemia" in its name, the World Health Organization (WHO) classifies CMML as a mixed myelodysplastic/myeloproliferative neoplasm (MDS/MPN). This classification reflects the disease's dual characteristics-features of myelodysplastic syndromes (MDS), which impact normal blood cell production, and myeloproliferative neoplasms (MPN), where bone marrow stem cells produce excessive blood cells, including red cells, white cells, or platelets.
Find out more about Chronic Myelocytic Leukemia medication @ https://www.delveinsight.com/report-store/chronic-myelocytic-leukemia-cml-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr
Chronic Myelocytic Leukemia Treatment Analysis: Drug Profile
Sabatolimab: Novartis Oncology
Sabatolimab (MBG 453) is a monoclonal antibody targeting T-cell immunoglobulin and mucin domain 3 (TIM-3), under development by Novartis Oncology. It is currently in Phase III clinical trials for the treatment of Chronic Myeloid Leukemia (CML).
Enasidenib: Servier
Enasidenib (AG 221) is an orally administered small molecule inhibitor of isocitrate dehydrogenase 2 (IDH2), developed by Servier. The drug is presently in Phase I clinical trials for the treatment of Chronic Myeloid Leukemia (CML).
Key Chronic Myelocytic Leukemia Therapies and Companies
• Imatinib: Novartis Pharmaceuticals
• Radotinib HCl: Il-Yang Pharm. Co., Ltd.
• Olverembatinib: Ascentage Pharma Group Inc.
• Venetoclax: AbbVie
• Sabatolimab: Novarits Oncology
• Enasidenib: Servier
Learn more about the novel and emerging Chronic Myelocytic Leukemia pipeline therapies @ https://www.delveinsight.com/report-store/chronic-myelocytic-leukemia-cml-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr
Chronic Myelocytic Leukemia Therapeutics Assessment
By Product Type
• Mono
• Combination
• Mono/Combination.
By Stage
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
By Route of Administration
• Oral
• Parenteral
• Intravitreal
• Subretinal
• Topical
By Molecule Type
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy
Scope of the Chronic Myelocytic Leukemia Pipeline Report
• Coverage: Global
• Key Chronic Myelocytic Leukemia Companies: Novartis Oncology, Servier, Eltrombopag, Immune-Onc Therapeutics, H3 Biomedicine, Chroma Therapeutics, Nerviano Medical Sciences, Astex Pharmaceuticals, Takeda Oncology, Argenx, Kura Oncology, Incyte Corporation, Genentech, Inc., Sensei Biotherapeutics, Pfizer, BioLite, Inc., Newave Pharmaceutical Inc., Ellipses Pharma, Eli Lilly and Company, Aprea Therapeutics, Treadwell Therapeutics, Prelude Therapeutics, Onconova Therapeutics, Immune Pharmaceuticals, Teva Pharmaceutical Industries, and others.
• Key Chronic Myelocytic Leukemia Pipeline Therapies: Imatinib, Radotinib, Olverembatinib, Venetoclax, Sabatolimab, Enasidenib, and others.
Dive deep into rich insights for drugs used for Chronic Myelocytic Leukemia treatment; visit @ https://www.delveinsight.com/report-store/chronic-myelocytic-leukemia-cml-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr
Table of Contents
1. Introduction
2. Executive Summary
3. Chronic Myelocytic Leukemia Pipeline: Overview
4. Analytical Perspective In-depth Commercial Assessment
5. Chronic Myelocytic Leukemia Pipeline Therapeutics
6. Chronic Myelocytic Leukemia Pipeline: Late-Stage Products (Phase III)
7. Chronic Myelocytic Leukemia Pipeline: Late-Stage Products (Phase III)
8. Chronic Myelocytic Leukemia Pipeline: Mid-Stage Products (Phase II)
9. Chronic Myelocytic Leukemia Pipeline: Early Stage Products (Phase I)
10. Therapeutic Assessment
11. Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Key Companies
14. Key Products
15. Unmet Needs
16. Market Drivers and Barriers
17. Future Perspectives and Conclusion
18. Analyst Views
19. Appendix
Contact Us:
Jatin Vimal
jvimal@delveinsight.com
+14699457679
Healthcare Consulting
https://www.delveinsight.com/consulting-services
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Chronic Myeloid Leukemia Pipeline: Driving Innovation with 25+ Pioneering Companies Advancing Groundbreaking Therapies here
News-ID: 3936870 • Views: …
More Releases from DelveInsight
Ischemic Stroke Clinical Trials 2025: Tenecteplase FDA Approval, Thrombectomy Up …
DelveInsight's "Ischemic Stroke - Clinical Trials, 2025" captures a rapidly evolving landscape in which improvements in acute reperfusion (thrombolysis and endovascular thrombectomy), adjunctive neuroprotection, and post-stroke recovery technologies are converging to reduce disability. In early 2025 the FDA approved tenecteplase (TNK) for acute ischemic stroke - a single-bolus thrombolytic that simplifies IV thrombolysis and may improve workflow and reperfusion outcomes compared with alteplase.
Endovascular device innovation continues in parallel: updated…
Attention Deficit Hyperactivity Disorder Clinical Trials 2025: 22+ Pipeline Ther …
DelveInsight's "Attention Deficit Hyperactivity Disorder - Clinical Trials, 2025" reviews over 22 therapies in development for ADHD, a highly prevalent neurodevelopmental disorder affecting both children and adults, with rising diagnosis rates across the 7MM. Traditionally managed with stimulant medications like methylphenidate and amphetamines, ADHD care is now undergoing a paradigm shift as pharmaceutical companies and digital health innovators explore new mechanisms of action and non-pharmacologic interventions.
The clinical pipeline is advancing…
Chronic Heart Failure Clinical Trials 2025: 25+ Pipeline Therapies, SGLT2 Inhibi …
DelveInsight's "Chronic Heart Failure - Clinical Trials, 2025" highlights 25+ therapies in development for CHF, a progressive condition marked by high morbidity and mortality. Beyond cornerstone treatments such as sacubitril/valsartan and SGLT2 inhibitors, companies like Cytokinetics, Bayer, AstraZeneca, and Eli Lilly are advancing novel agents targeting fibrosis, energetics, and neurohormonal pathways.
The pipeline spans soluble guanylate cyclase stimulators, myosin modulators, metabolic agents, and anti-fibrotic therapies, with regenerative and gene-based approaches also…
Beta-Thalassemia Clinical Trials 2025: 22+ Pipeline Therapies, Gene Editing, and …
DelveInsight's "Beta-Thalassemia - Clinical Trials, 2025" reviews over 22 therapies in development for beta-thalassemia, a rare inherited blood disorder characterized by impaired hemoglobin production and chronic anemia, often requiring lifelong blood transfusions and iron chelation therapy. While allogeneic stem cell transplantation remains the only established cure, its limitations-including donor availability and transplant-related risks-have driven intense innovation toward disease-modifying and potentially curative approaches.
The clinical pipeline is rapidly advancing with gene therapies,…
More Releases for Chronic
Chronic Pain Treatment Market - Relieving Chronic Pain: Discover the Latest Inno …
Newark, New Castle, USA: The "Chronic Pain Treatment Market" provides a value chain analysis of revenue for the anticipated period from 2022 to 2030. The report will include a full and comprehensive analysis of the business operations of all market leaders in this industry, as well as their in-depth market research, historical market development, and information about their market competitors
Chronic Pain Treatment Market: https://www.growthplusreports.com/report/chronic-pain-treatment-market/8030
This latest report researches the industry structure,…
Refractory Chronic Cough Therapeutics Market - Silencing the Cough: Innovative T …
Newark, New Castle, USA: The "Refractory Chronic Cough Therapeutics Market" provides a value chain analysis of revenue for the anticipated period from 2022 to 2030. The report will include a full and comprehensive analysis of the business operations of all market leaders in this industry, as well as their in-depth market research, historical market development, and information about their market competitors
Refractory Chronic Cough Therapeutics Market: https://www.growthplusreports.com/report/refractory-chronic-cough-therapeutics-market/7991
This latest report researches the…
Chronic Pulmonary Aspergillosis Drugs Market - Revitalizing Lungs: Revolutionary …
Newark, New Castle, USA - new report, titled Chronic Pulmonary Aspergillosis Drugs Market The report has been put together using primary and secondary research methodologies, which offer an accurate and precise understanding of the Chronic Pulmonary Aspergillosis Drugs market. Analysts have used a top-down and bottom-up approach to evaluate the segments and provide a fair assessment of their impact on the global Chronic Pulmonary Aspergillosis Drugs market. The report offers…
Chronic Hepatitis Therapeutics Market - Empowering Liver Health, Defying Chronic …
Newark, New Castle, USA - new report, titled Chronic Hepatitis Therapeutics Market The report has been put together using primary and secondary research methodologies, which offer an accurate and precise understanding of the Chronic Hepatitis Therapeutics market. Analysts have used a top-down and bottom-up approach to evaluate the segments and provide a fair assessment of their impact on the global Chronic Hepatitis Therapeutics market. The report offers an overview of…
Chronic Phase Chronic Myeloid Leukemia Market to Witness Growth by 2032, Estimat …
DelveInsight's "Chronic Phase Chronic Myeloid Leukemia Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of Chronic Phase Chronic Myeloid Leukemia , historical and forecasted epidemiology as well as the Chronic Phase Chronic Myeloid Leukemia market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.
The Chronic Phase Chronic Myeloid Leukemia market report provides current treatment practices, emerging drugs, the market share…
Boot chronic pain
For immediate release
Due to our rushed lives and stressful environment, many people are suffering from chronic pain and fatigue.
We feel permanently tired and are barely able to get through our normal day. One is able to change this status when following the guidelines the book "Tired of being Tired to the point of being Gatvol (Fed Up). Some people will need a team of medical practitioners to help them…
